← Back

Liminatus Pharma, Inc. Class A Common Stock

Liminatus Pharma, Inc. is a pre-clinical stage biopharmaceutical company based in Cerritos, California, focused on developing cancer therapies in the United States. Its lead candidate, IBA101, is a humanized anti-CD47 monoclonal antibody in Phase I clinical trials for advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018.

Country
Price · split & dividend adjusted
News & notes moving LIMN
LIMN

Liminatus Pharma Announces 1-for-50 Reverse Stock Split

Liminatus Pharma, Inc. announced that its board of directors has approved a 1-for-50 reverse stock split of its common stock, which was approved by stockholders at the company's 2026 Annual Meeting held on August 3, 2026. The reverse split will take effect at the close of trading on August 20, 2026, and the stock is expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market under the symbol LIMN at the market open on August 21, 2026. Every 50 issued and outstanding shares will be automatically combined into one share, with no fractional shares issued; stockholders entitled to fractional shares will have them rounded up to the nearest whole share. The reverse split has no effect on the par value or authorized shares, and each stockholder's proportionate ownership interest and voting power will remain unchanged except for nominal adjustments from fractional share treatment. If implemented as of July 2, 2026, total outstanding shares would be reduced from 67,160,362 to approximately 1,343,208, with proportionate adjustments made to outstanding equity awards, warrants, and other convertible securities.
LIMN
GlobeNewswire·31dRead more →
LIMN

Liminatus Pharma Transfers to Nasdaq Capital Market, Gets Bid Price Extension

Liminatus Pharma announced its common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective August 4, 2026, and that the Nasdaq Hearings Panel granted the company additional time to regain compliance with the minimum bid price requirement. The transfer allows the stock to continue trading on Nasdaq under ticker LIMN, and the Panel gave the company until September 3, 2026 to demonstrate compliance with the Bid Price Rule. Chief Financial Officer Scott Dam said maintaining the Nasdaq listing remains an important priority as the company executes its corporate and clinical development strategy.
LIMN
GlobeNewswire·37dRead more →
Biotech & Genomic Medicine▲

Liminatus Pharma Amends Merger Agreement With InnocsAI to Expand Oncology Pipeline

Liminatus Pharma has amended and restated its definitive merger agreement with InnocsAI LLC, allowing the deal to close prior to obtaining stockholder approval, with closing now expected on July 2, 2026. Under the amended terms, InnocsAI equity holders will receive a mix of Liminatus common stock and newly designated non-voting convertible preferred stock, issued at $0.20 per common share, representing an implied transaction value of approximately $320 million, plus contingent value rights tied to 20% of future net proceeds from certain strategic transactions involving the acquired assets. InnocsAI holders will receive Liminatus common shares up to the maximum allowed without prior stockholder approval under Nasdaq rules, estimated at 19.99% of outstanding shares immediately before closing, with the remainder in non-voting convertible preferred stock that can only be converted into common shares once stockholder approval is obtained. Liminatus CEO Chris Kim stated that the merger is a transformational step to build a diversified oncology biotechnology company, with InnocsAI's cell therapy platform complementing Liminatus' immuno-oncology programs and broadening its pipeline.
LIMN ▲
Biotech & Genomic Medicine
RTTNews·80dRead more →
© 2026 MarketDXAsset